Followers | 177 |
Posts | 24458 |
Boards Moderated | 13 |
Alias Born | 04/03/2002 |
Wednesday, August 11, 2021 2:02:02 PM
https://www.gaintherapeutics.com/about/overview.html
LEADING THE DISCOVERY
of Allosteric Binding Sites to Create New Medicines
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform.
By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders.
Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson’s disease. When a protein misfolds, its 3D structure is disrupted and it can no longer function properly. While some treatments are available for these types of disorders, they have significant limitations.
Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
Recent GANX News
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 04/24/2024 01:25:00 PM
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer • GlobeNewswire Inc. • 04/08/2024 01:25:00 PM
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/01/2024 01:25:00 PM
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Gain Therapeutics to Present at Public Ventures Discovery Day • GlobeNewswire Inc. • 03/15/2024 06:30:11 PM
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 02/27/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:17 PM
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight • GlobeNewswire Inc. • 02/14/2024 05:29:34 PM
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 02:56:04 PM
- Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:26:33 PM
- Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2024 09:09:27 PM
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024 • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/02/2024 05:15:12 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:03 PM
- Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model • GlobeNewswire Inc. • 12/01/2023 01:00:00 PM
- Gain Therapeutics to Participate in AI Driven Drug Discovery Summit • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option • GlobeNewswire Inc. • 11/24/2023 06:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/24/2023 11:07:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 10:27:26 PM
- Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants • GlobeNewswire Inc. • 11/21/2023 01:54:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/20/2023 09:22:52 PM
- Gain Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 11/20/2023 09:03:43 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM